Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1.

BACKGROUND High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is used for the treatment of hemato-oncologic malignancies. In this study, we measured the effect of HDC/ASCT on plasma concentrations of antiangiogenic soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and of leukapheresis products (LP) and patient serum on chick chorioallantoic (CAM) angiogenesis. MATERIALS AND METHODS VEGFR1- and CD34-expressing cells of leukapheresis products were analyzed by flow cytometry. Alternatively spliced isoforms of VEGFR1 mRNA were quantified using reverse transcription PCR. RESULTS Plasma concentrations of sVEGFR1 decreased after HDC, but significantly increased after ASCT. In the CAM assay, sera of patients elicited a proangiogenic effect before and after HDC, but a strong antiangiogenic response after ASCT, comparable to that of bevacizumab at therapeutic concentrations. LP contains high concentrations of sVEGFR1, and high density of VEGFR1(+) neutrophilic granulocytes, in which mRNA expression is shifted toward the soluble VEGFR1 isoform. CONCLUSION Neutrophil-derived antiangiogenic sVEGFR1 within the LP may contribute to the therapeutic efficacy of ASCT.

[1]  J. Hamilton.  Colony-stimulating factors in inflammation and autoimmunity , 2008, Nature Reviews Immunology.

[2]  M. Conforti,et al.  Autologous stem cell transplantation improves microcirculation in systemic sclerosis , 2008, Annals of the rheumatic diseases.

[3]  Takeshi Kimura,et al.  Analysis of Serum Angiogenic Factors in a Young Multiple Myeloma Patient with High-Output Cardiac Failure , 2007, International journal of hematology.

[4]  U. Ikeda,et al.  Local implantation of autologous mononuclear cells from bone marrow and peripheral blood for treatment of ischaemic digits in patients with connective tissue diseases. , 2007, Rheumatology.

[5]  D. Ribatti,et al.  Expression and Functions of the Vascular Endothelial Growth Factors and Their Receptors in Human Basophils1 , 2006, The Journal of Immunology.

[6]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[7]  A. Zeiher,et al.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. , 2006, The New England journal of medicine.

[8]  E. Taraldsrud,et al.  Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. , 2006, The New England journal of medicine.

[9]  S. Indraccolo,et al.  Dormant Tumors Awaken by a Short-Term Angiogenic Burst: The Spike Hypothesis , 2006, Cell cycle.

[10]  Seung‐Woo Cho,et al.  Angiogenesis Facilitated by Autologous Whole Bone Marrow Stem Cell Transplantation for Buerger's Disease , 2006, Stem cells.

[11]  W. Jiang,et al.  Pigment Epithelium-derived Factor Inhibits Angiogenesis via Regulated Intracellular Proteolysis of Vascular Endothelial Growth Factor Receptor 1* , 2006, Journal of Biological Chemistry.

[12]  R. Stupp,et al.  Monitoring multiple angiogenesis‐related molecules in the blood of cancer patients shows a correlation between VEGF‐A and MMP‐9 levels before treatment and divergent changes after surgical vs. conservative therapy , 2006, International journal of cancer.

[13]  J. Jankowski,et al.  Soluble Vascular Endothelial Growth Factor Receptor-1 (sFLT-1) Mediates Downregulation of FLT-1 and Prevents Activated Neutrophils From Women With Preeclampsia From Additional Migration by VEGF , 2005, Circulation research.

[14]  D. Hicklin,et al.  Granulocyte colony‐stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Lee M Ellis,et al.  Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells , 2005, Oncogene.

[16]  Yijie Wang,et al.  GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. , 2004, Immunity.

[17]  T. Naoe,et al.  Rapid Communication Molecular Evaluation of Endothelial Progenitor Cells in Patients with Ischemic Limbs Therapeutic Effect by Stem Cell Transplantation Vascular Biology , 2022 .

[18]  Bernd Hertenstein,et al.  Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial , 2004, The Lancet.

[19]  Ruud P. M. Dings,et al.  Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF , 2004, International journal of cancer.

[20]  C. Legrand,et al.  Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism , 2004, Laboratory Investigation.

[21]  F. Kudo,et al.  Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia. , 2003, International angiology : a journal of the International Union of Angiology.

[22]  F. Lanza,et al.  In vitro assessment of bone marrow endothelial colonies (CFU-En) in non-Hodgkin's lymphoma patients undergoing peripheral blood stem cell transplantation , 2003, Bone Marrow Transplantation.

[23]  Christoph Dehio,et al.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.

[24]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[25]  J. Živný,et al.  Expression of genes regulating angiogenesis in human circulating hematopoietic cord blood CD34+/CD133+ cells , 2003, European journal of haematology.

[26]  Sung-Bae Kim,et al.  Comparison of Microvessel Density Before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications: Multicenter Trial , 2002, International journal of hematology.

[27]  M. Makuuchi,et al.  G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. , 2002, Biochemical and biophysical research communications.

[28]  K. Shimada,et al.  Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial , 2002, The Lancet.

[29]  F. Selheim,et al.  Identification of functional VEGF receptors on human platelets , 2002, FEBS letters.

[30]  O. Sezer,et al.  Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy , 2001, European journal of haematology.

[31]  R. Fonseca,et al.  Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma , 1999, Leukemia.

[32]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Martiny-Baron,et al.  Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. , 1997, Cancer research.

[34]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[35]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[36]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[37]  A. Nademanee,et al.  High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Labopin,et al.  Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study. , 1992, Leukemia.

[39]  Robert Langer,et al.  Angiogenesis, Key principles, Science, Technology, Medicine , 1992 .

[40]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[41]  G. Tricot,et al.  Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Zander,et al.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. , 1986, Blood.

[43]  W. Dameshek,et al.  Autologous bone marrow infusion as an adjunct in therapy of malignant disease. , 1959, Blood.

[44]  Uichi Ikeda,et al.  Changes in angiogenesis-related factors in serum following autologous bone marrow cell implantation for severe limb ischemia. , 2008, Expert opinion on biological therapy.

[45]  Nasim Akhtar,et al.  Angiogenesis assays: a critical overview. , 2003, Clinical chemistry.

[46]  A. Gratwohl,et al.  The use of high dose immunoablative therapy with hematopoietic stem cell support therapy in the treatment of severe autoimmune diseases , 2002, International journal of hematology.